Literature DB >> 2506805

In vitro activity of S-ofloxacin.

H C Neu1, N X Chin.   

Abstract

S-Ofloxacin, the optically active form of ofloxacin, was twice as active as the S,R mixture of ofloxacin against members of the family Enterobacteriaceae, Pseudomonas aeruginosa, and gram-positive species. Of the Enterobacteriaceae, 90% were inhibited by less than or equal to 1 microgram/ml and 90% of Staphylococcus aureus and Streptococcus pyogenes isolates were inhibited by 0.5 microgram/ml. Bacteroides fragilis was inhibited by 4 micrograms/ml. Organisms resistant to ofloxacin were resistant to S-ofloxacin. Like ofloxacin activity, the activity of S-ofloxacin was reduced by Mg2+ and by acid pH. Spontaneous mutational resistance to S-ofloxacin was similar to that to ofloxacin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2506805      PMCID: PMC176070          DOI: 10.1128/AAC.33.7.1105

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers.

Authors:  J S Wolfson; D C Hooper; E Y Ng; K S Souza; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

2.  In vitro activity of DR-3355, an optically active ofloxacin.

Authors:  T Une; T Fujimoto; K Sato; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

3.  Inhibition of DNA gyrase by optically active ofloxacin.

Authors:  M Imamura; S Shibamura; I Hayakawa; Y Osada
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

4.  Synthesis and antibacterial activities of optically active ofloxacin.

Authors:  I Hayakawa; S Atarashi; S Yokohama; M Imamura; K Sakano; M Furukawa
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

5.  Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969).

Authors:  A M Espinoza; N X Chin; A Novelli; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  Factors influencing the in vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620.

Authors:  L Hirschhorn; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

7.  Synthesis, absolute configuration, and antibacterial activity of 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H- benzo[ij]quinolizine-2-carboxylic acid.

Authors:  J F Gerster; S R Rohlfing; S E Pecore; R M Winandy; R M Stern; J E Landmesser; R A Olsen; W B Gleason
Journal:  J Med Chem       Date:  1987-05       Impact factor: 7.446

  7 in total
  22 in total

1.  In vitro efficacy of the successive or staggered use of eardrops.

Authors:  M Tayyar Kalcioglu; Orhan Ozturan; Riza Durmaz; Elif Aktas
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-22       Impact factor: 2.503

2.  Determination of activities of levofloxacin, alone and combined with gentamicin, ceftazidime, cefpirome, and meropenem, against 124 strains of Pseudomonas aeruginosa by checkerboard and time-kill methodology.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

3.  Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.

Authors:  E J Goldstein; D M Citron; S Hunt Gerardo; M Hudspeth; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.

Authors:  S K Spangler; G Lin; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

6.  In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.

Authors:  E J Goldstein; D M Citron; M Hudspeth; S Hunt Gerardo; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

7.  Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem.

Authors:  S K Spangler; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model.

Authors:  S L Kang; M J Rybak; B J McGrath; G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

9.  Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin.

Authors:  M G Cormican; R N Jones
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

10.  Activity of levofloxacin in a murine model of tuberculosis.

Authors:  S P Klemens; C A Sharpe; M C Rogge; M H Cynamon
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.